BioCardia, Inc. has received a positive assessment from Japan’s Pharmaceutical and Medical Device Agency (PMDA) regarding its CardiAMP® Cell Therapy for ischemic heart failure. The PMDA has indicated that the clinical safety and efficacy data gathered in the U.S. is likely sufficient for market clearance, highlighting a significant step toward the introduction of this minimally invasive biologic therapy in Japan. The meeting facilitated alignment on the use of foreign data, patient indications, and the necessity for ongoing post-marketing studies, with BioCardia awaiting further details from the PMDA.

The CardiAMP Cell Therapy employs autologous bone marrow cells delivered via a catheter to enhance capillary density and mitigate myocardial tissue fibrosis, addressing microvascular dysfunction in heart failure patients. This therapy has already garnered FDA Breakthrough designation and is supported by the Maryland Stem Cell Research Fund, with reimbursement from CMS. The forthcoming approval in Japan would mark a pivotal advancement in the treatment landscape for ischemic heart failure, potentially improving patient outcomes significantly.

This development has implications for the broader field of regenerative medicine and cardiac therapies. The acceptance of foreign clinical data by regulatory bodies like the PMDA could streamline the pathway for other innovative therapies seeking approval in international markets. As BioCardia moves toward market clearance, this could accelerate timelines for similar therapies, enhancing the pace of innovation in the treatment of cardiovascular diseases and potentially reshaping global standards for cell-based therapies.

Source: globenewswire.com